Lunic Endoprosthesis for Pelvic Reconstruction: A Canadian Experience

Description

This presentation discusses a retrospective multicentric study conducted by the McGill University Sarcoma Unit, focusing on the outcomes of the Lumic prosthesis used in orthopedic surgery for pelvic tumor resection. The study highlights the complexities and challenges of reconstructing bony and soft tissue defects post-resection. While various reconstruction methods have been tried, the Lumic endoprosthesis, introduced in 2008, is notable for its modularity, allowing for better adaptation and potentially reduced dislocation risks.



The study included 16 patients, primarily with primary sarcoma, and assessed surgical and functional outcomes after an average follow-up of 28 months. Notably, the mean operative time was extensive, averaging 555 minutes, with considerable blood loss reported. Despite high infection rates (50%) and dislocations in 30% of patients, the Lumic prosthesis showed promise due to no recorded aseptic loosening cases.



The research indicates a correlation between prolonged surgical time and increased infection risks. Most surgeries were one-stage procedures, but the study suggests reconsidering two-stage approaches due to higher infection rates observed in these cases. The results reveal that 70% of patients retained their original implants at the last follow-up, with an average MSTS score of 55% reflecting the overall functional outcome.



The findings contribute to understanding the performance of the Lumic prosthesis in North America, emphasizing its value as a reconstruction tool despite the notable complications. A need for larger cohorts and longer follow-ups is recognized to solidify these findings.

Specialties